How Infusion Centers and Specialty Pharmacies Source High-Cost Injectables Without Getting Burned by Shortages

Your Patient’s Biologic Costs $8,000 a Dose. The Supplier Just Called to Say It Is on Allocation.

This is the phone call that keeps infusion center administrators up at night. A patient is scheduled for infusion. The medication is a specialty biologic. Your facility ordered it three weeks ago. Today the supplier is telling you they can fulfill only 40 percent of your order because the manufacturer placed the product on allocation. The remaining 60 percent will ship next month, maybe. Your scheduling team now has to decide which patients receive their infusion on time and which ones get rescheduled.

If you operate an infusion center, specialty pharmacy, or ambulatory infusion center (AIC), this scenario is not hypothetical. High-cost specialty injectables — biologics, oncology agents, immunoglobulins, and growth hormones — carry a procurement risk profile fundamentally different from generic medications. The products cost more, the supply chain is thinner, and the patients depending on them have conditions that do not tolerate treatment delays.

This guide breaks down how infusion centers and specialty pharmacies manage specialty injectable procurement in an environment where shortages are the rule, not the exception.

Why Specialty Injectables Break the Standard Procurement Playbook

Specialty injectables are not expensive generics. They are a different product category with their own supply dynamics. The FDA Drug Shortages database tracks hundreds of active shortages, and the ones that hit infusion center drug sourcing hardest share common traits: a small manufacturer base, complex fill-finish requirements, cold-chain distribution, and patient populations with limited therapeutic alternatives.

Consider manufacturing concentration. Industry analysts estimate the sterile injectable contract manufacturing market will grow into the tens of billions of dollars by the end of the decade, yet fewer than 20 contract development and manufacturing organizations (CDMOs) globally offer commercial-scale capacity for antibody-drug conjugates, and cell and gene therapy batches often run under 100 units. When Pfizer announced the closure of two legacy U.S. sterile manufacturing plants in late 2024 and shifted production to contract partners, the redistribution created weeks of transition risk for the drugs those plants made.

Add the active pharmaceutical ingredient (API) problem. The FDA has reported that roughly 80 percent of API manufacturing sites supplying the U.S. market are located overseas, primarily in India and China. For specialty injectables built on single-source APIs, a quality event or export restriction at one foreign facility can trigger a nationwide finished-product shortage. A purchasing agreement with a U.S. distributor does not insulate a facility from a disruption eight time zones away.

The Specialty Injectable Categories Infusion Centers Actually Manage

• Biologics (anti-inflammatory): Rituximab biosimilars, infliximab, adalimumab
• Oncology injectables: Methotrexate (Rasuvo), carboplatin, paclitaxel, rituximab
• Immunoglobulins: IVIG, SCIG
• Growth hormones: Somatropin (Norditropin, Genotropin, Humatrope)
• Specialty antibiotics: Primaxin (imipenem-cilastatin), daptomycin, vancomycin
• Corticosteroid injectables: Solu-Medrol (methylprednisolone), dexamethasone
• Hormone / GnRH agonists: Triptorelin pamoate, leuprolide

The common thread across these categories: unit costs are high, treatment courses are long, and the clinical consequences of a missed dose can be severe. An oncology patient on a dose-dense protocol cannot skip a week. An IVIG patient with primary immunodeficiency requires consistent plasma levels.

How to Build a Procurement Strategy That Protects Your Patients

Discipline 1: Participate in Commitment-Based Shortage Programs

Premier Inc. and Vizient both operate commitment-based drug shortage programs that prioritize allocation for members. Members of the National Home Infusion Association (NHIA) often access pooled purchasing agreements that extend leverage across smaller provider networks. Commitment programs reward facilities that pre-commit volume with preferred allocation during shortage events — an insurance premium that pays out when the market tightens.

Discipline 2: Diversify Across Biosimilars

For categories where biosimilars exist — rituximab, trastuzumab, epoetin, filgrastim, and a growing list of others tracked by the FDA Biosimilar Product Information list — maintain active relationships with multiple biosimilar manufacturers. A single-reference-product strategy exposes a facility to every shortage event affecting that brand. Facilities qualifying secondary biosimilar sources can review current availability in our Rx prescriptions catalog.

Discipline 3: Build Inventory Buffers Strategically

For highest-risk products — oncology injectables, IVIG, and specialty antibiotics such as imipenem — maintain 30 to 60 days of inventory when storage capacity, shelf life, and cash flow permit. Stratify buffers by risk class rather than applying a uniform par level across the catalog. Uniform par levels waste working capital on stable SKUs while leaving exposure on the volatile ones that matter most.

Discipline 4: Verify DSCSA Compliance at Every Distributor

The Drug Supply Chain Security Act (DSCSA) reached its final implementation milestone in November 2024, requiring package-level electronic traceability across trading partners. Every specialty injectable distributor your facility uses must deliver electronic T3 data (Transaction Information, Transaction History, Transaction Statement), authenticate saleable returns, and maintain auditable chain-of-custody records. Scanned paper documentation no longer satisfies the requirement — suppliers who cannot produce EPCIS-formatted transaction data should not be on your approved list. The same ATP verification discipline applies across every prescription category; our GI drug procurement guide walks through the identical DSCSA checks for preservative-free injectables and phosphate binders.

Procurement Patterns That Fail

The infusion centers and specialty pharmacies that get caught off guard during allocation events usually share the same procurement anti-patterns. Audit your operation against this list:

• Brand loyalty that blocks biosimilar adoption until the reference product is unavailable. By the time the shortage hits, allocation is already tight.
• Single-source purchasing built on price rather than resilience. The lowest quote on the day of the RFP is the highest cost during an allocation event.
• Inventory management that does not differentiate high-risk from low-risk. Uniform par levels waste cash on stable SKUs and leave exposure on volatile ones.
• Treating DSCSA compliance as a checkbox. Auditable traceability is an operational requirement with real enforcement consequences, not a documentation task.

Your Specialty Injectable Patients Cannot Afford Supply Chain Roulette

USA MedPremium is a DSCSA-compliant, fully licensed pharmaceutical distributor built for infusion centers and specialty pharmacies that cannot absorb a missed dose. For specialty injectable procurement specifically, that means:

• Biologics and biosimilars across anti-inflammatory, oncology, and hematology categories — rituximab, trastuzumab, infliximab, adalimumab, and the growing biosimilar shelf
• Oncology injectables including methotrexate, carboplatin, paclitaxel, and the chemotherapy agents most often on shortage
• Immunoglobulins (IVIG and SCIG) sourced across multiple plasma-derivative manufacturers to absorb plasma-supply volatility
• Specialty antibiotics and growth hormones — imipenem-cilastatin, daptomycin, vancomycin, and somatropin products — with shortage-aware allocation for partner facilities

We source across multiple manufacturers, maintain full DSCSA compliance with electronic traceability, and ship from Florida to infusion centers and specialty pharmacies nationwide.

View our extended Pharmacy and prescription category for the full specialty injectable footprint — biologics, oncology agents, immunoglobulins, specialty antibiotics, and growth hormones.

Register for a free account to view tiered pricing, compare volume thresholds, and calculate exact savings before committing.